Recombinant Human Cripto-1 Protein(Fc Tag)

SKU: PDMH100311

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Others

Abbreviation:Cripto-1

Target Synonym:TDGF;Teratocarcinoma-derived growth factor;Epidermal growth factor-like cripto protein CR;TDGF1;CR;CRGF;CRIPTO;Cripto-1 growth factor;Epidermal growth factor-like cripto protein CR1;Teratocarcinoma-derived growth factor 1;Cripto 1;Cripto 1 growth factor;Cripto1 growth factor;Epidermal growth factor like cripto protein CR1;TDGF 1;Teratocarcinoma derived growth factor 1

Research Areas:Stem Cells;Developmental Biology

Conjugation:

Target Species:Human

Expression Host:Mammalian

Application:

Fusion tag:C-Fc

UNIProt ID:P13385

Accession:P13385

Background:Cripto/TDGF1 is a member of the epidermal growth factor (EGF)-Cripto , Frl-1 , and Cryptic (CFC) family. EGF-CFC family member proteins share a variant EGF-like motif , a conserved cysteine-rich domain , and a C-terminal hydrophobic region. Before gastrulation , Cripto is asymmetrically expressed in a proximal–distal gradient in the epiblast , and subsequently is expressed in the primitive streak and newly formed embryonic mesoderm. These proteins play key roles in intercellular signaling pathways during vertebrate embryogenesis. Mutations in Cripto/TDGF1 can cause autosomal visceral heterotaxy. Cripto/TDGF1 is involved in left-right asymmetric morphogenesis during organ development. Cripto signalling is essential for the conversion of a proximal–distal asymmetry into an orthogonal anterior–posterior axis. The mechanism of inhibitory effects of the Cripto includes both cancer cell apoptosis , activation of c-Jun-NH(2)-terminal kinase and p38 kinase signaling pathways and blocking of Akt phosphorylation. Thus , Cripto is a unique target , and Immunohistochemistry to Cripto could be of therapeutic value for Human cancers.

Concentration:

Activity:Not validated for activity

Sequence:Leu31-Ser169

Purity: > 90% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Endotoxin:< 1.0 EU/mg of the protein as determined by the LAL method.

Calculated MW:40.2 kDa

ObservedMW:40 kDa